ISAL 2019 | Use of gemtuzumab ozogamicin in CBF-AML

Alan Burnett

Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, discusses the clinical development of gemtuzumab ozogamicin, focusing on its use in core binding factor (CBF) acute myeloid leukemia (AML) and the remaining questions in this field. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Share this video